Kurs & Likviditet
|Lista||First North Stockholm|
|2022-05-20||Ordinarie utdelning NEOD 0.00 SEK|
|2022-02-25||Extra Bolagsstämma 2022|
|2021-05-27||Ordinarie utdelning NEOD 0.00 SEK|
|2020-11-19||Extra Bolagsstämma 2020|
|2020-05-29||Ordinarie utdelning NEOD 0.00 SEK|
|2020-01-28||Extra Bolagsstämma 2019|
|2019-05-24||Ordinarie utdelning NEOD 0.00 SEK|
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
NeoDynamics AB (publ) ("NeoDynamics" or "the Company") announces today that the rights issue of shares (the "Rights Issue") has been completed. The subscription period ran from, and including, March 9, 2022, up to and including, March 23, 2022. 32,002,336 shares, corresponding to approximately 53 per cent of the Rights Issue, were subscribed for by the exercise of subscription rights. Furthermore, 492,750 shares were subscribed for without subscription rights, corresponding to approximately 1 per cent of the Rights Issue. The remaining 27,755,506 shares, corresponding to approximately 46 per cent of the Rights Issue, were allocated to the guarantors in the Rights Issue. Through the Rights Issue, NeoDynamics receives proceeds amounting to approximately SEK 69 million before the deduction of costs related to the Rights Issue.
Outcome of the Rights Issue
The Rights Issue comprised a maximum of 60,250,592 shares, of which 32,002,336 shares, corresponding to approximately 53 percent of the Rights issue, have been subscribed for by exercise of subscription rights (including subscription undertakings). A total of 492,750 shares, corresponding to approximately 1 percent of the Rights Issue, have been subscribed for without use of subscription rights. Thus, 32,495,086 shares, corresponding to approximately 54 percent of the offered shares, have been subscribed for with and without the use of subscription rights. The remaining 27,755,506 shares, corresponding to approximately 46 per cent of the Rights Issue, were allocated to the guarantors in the Rights Issue.
Notification regarding allocation
Allocation of shares has been made in accordance with the allocation principles described in the prospectus that was published in connection with the Rights Issue. Notification regarding allocation of shares subscribed for without the use of subscription rights will be made by distribution of contract notes by post to those subscribers who have been allotted shares in the Rights Issue. Allocated shares subscribed for without the use of subscription rights shall be paid for in accordance with the instructions in the contract note.
Trading in BTA
Trading in BTA (Sw. betald tecknad aktie, which translates to paid subscribed share) is currently taking place at the Spotlight Stock Market and will cease when the Rights Issue has been registered by the Swedish Companies Registration Office. BTA:s will then be converted to ordinary shares.
Number of shares and share capital
Through the Rights Issue, the number of shares in the Company will increase by 60,250,592 shares to 120,501,184 shares, resulting in an increase in the share capital of SEK 6,025,059.20 to SEK 12,050,118.40.
Redeye AB acts as financial advisor, Advokatfirman Lindahl KB acts as legal advisor and Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.
For further information, please contact:
Anna Eriksrud, CEO
Phone: +46 708 444966
NeoDynamics AB (publ) is a Swedish medical technology company that works to improve the diagnosis and treatment of cancer. The company's first product NeoNavia®, which is a new pulse biopsy system for ultrasound-guided tissue sampling, is now being introduced to the market. The biopsy system is based on a patented pulse technology based on research at Karolinska Institutet in Sweden. NeoNavia® is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breasts and lymph nodes of over 500 patients.
NeoNavia is a modern biopsy system with a completely new patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. It consists of a base unit, a handset and three types of biopsy needles. Each needle type is driven by the new pulse technology that provides a more controlled needle insertion and precise placement of the needle in the tumor while enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer doctors and patients a precise and reliable tissue sampling that enables a correct diagnosis and individualized treatment.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in NeoDynamics. No action has been taken and no measures will be taken to permit a public offering in any jurisdiction other than Sweden.
This release is not a prospectus in accordance to the definition in the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in NeoDynamics. A prospectus has been prepared and in connection with the Rights Issue and has been reviewed and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) which is the national competent authority in Sweden with regard to the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 (k) of the Prospectus Regulation this press release constitutes an advertisement.
The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in NeoDynamics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.
Within the European Economic Area ("EEA"), no public offering of shares or other securities ("Securities") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.